Therapeutic vaccination strategies to treat nasopharyngeal carcinoma

Research output: Contribution to journalReview articlepeer-review

Authors

Colleges, School and Institutes

External organisations

  • University of Birmingham
  • Cancer Immunology and Immunotherapy Centre

Abstract

Epstein-Barr virus (EBV) infects most people worldwide. EBV has oncogenic potential and is strongly associated with several lymphomas and carcinomas, including nasopharyngeal carcinoma (NPC), that together total 200,000 cases of cancer each year. All EBV-associated cancers express viral proteins that allow highly selective immunotherapeutic targeting of the malignant cells. A number of therapeutic EBV vaccines have been tested in clinical trials with evidence of immune boosting and clinical responses in NPC patients. Therapeutic vaccination could be used after adoptive T-cell transfer to increase and sustain the number of infused T-cells or combined with immunotherapies acting at different stages of the cancer immunity cycle to increase efficacy. The therapeutic EBV vaccines tested to date have been well tolerated with minimal off-target toxicity. A safe therapeutic vaccine that was also able to be mass produced could, in principle, be used to vaccinate large numbers of patients after first line therapy to reduce recurrence.

Details

Original languageEnglish
Article number23
JournalChinese Clinical Oncology
Volume5
Issue number2
Publication statusPublished - 1 Apr 2016

Keywords

  • Immunotherapy, PD-L1, Protein Death receptor 1 (PD1), Tumor

ASJC Scopus subject areas

Sustainable Development Goals